Gene Therapy Lyfgenia denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues Quantity-Limit Denials for Lyfgenia

Lyfgenia (lovotibeglogene autotemcel) is a one-time gene therapy for sickle cell disease. Because a single administration constitutes the entire course of treatment, quantity-limit denials often arise from a mismatch between how Aetna's system codes the product (sometimes as a refillable drug) and the clinical reality of a single-administration gene therapy. The denial is administratively generated rather than clinically driven, which makes it among the more straightforward to overturn.

## Why This Denial Is Appealable

The FDA-approved prescribing label defines the authorized administration regimen. If your physician's order and the submitted claim match that label exactly, the quantity-limit denial lacks a clinical basis. Aetna must cover services that are medically necessary and consistent with the FDA-approved indication — a single-course administration cannot exceed a quantity limit designed for ongoing refills.

## Your Appeal Rights and Timeline

• Internal appeal: Submit within the timeframe stated in your denial letter (typically 180 days). Aetna must issue a decision within 30 days for pre-service appeals or 60 days for post-service claims.
• External review (ACA §2719): If the internal appeal is denied, you have the right to an independent external review. The window to request external review is generally 4 months from the date of the final internal denial. An independent review organization (IRO) — not Aetna — will make the binding determination.
• Expedited review: If your condition is urgent or the treatment is time-sensitive, request expedited internal and external review simultaneously. Decisions are typically required within 72 hours.
• ERISA §503: If your coverage is through an employer-sponsored plan, ERISA's full-and-fair review protections also apply, including the right to all documents used in the coverage determination.

## Documentation to Gather

1. Diagnosis confirmation: Pathology or genetic laboratory reports confirming the specific sickle cell disease genotype that matches the FDA-approved indication. 2. Prescribing order: The exact administration order from the treating hematologist, mirroring the FDA label's authorized regimen. 3. Medical necessity letter: A detailed letter from the prescribing physician explaining why a single-course administration is the complete, label-directed treatment and cannot logically be subject to recurring quantity limits. 4. Billing documentation: Confirm with the specialty pharmacy or treatment center that the claim was coded correctly as a one-time gene therapy administration.

## Criteria-Mapping Structure

Pull a copy of Aetna's current published clinical policy for gene therapies or for Lyfgenia specifically. For each requirement listed, document the corresponding fact from the patient chart:

| Policy Requirement | Chart / Label Evidence | |---|---| | FDA-approved indication confirmed | [Diagnosis code + genotype result] | | Authorized administration regimen | [Prescribing order matching label] | | Treating facility certification | [Certified treatment center documentation] | | Quantity consistent with label | [Single-administration order on file] |

Present this table in your appeal letter so the reviewer can match each criterion to the evidence without searching through the record.